Simulations Plus Inc
NASDAQ:SLP

Watchlist Manager
Simulations Plus Inc Logo
Simulations Plus Inc
NASDAQ:SLP
Watchlist
Price: 28.34 USD 0.04%
Market Cap: 568.8m USD
Have any thoughts about
Simulations Plus Inc?
Write Note

Simulations Plus Inc
Net Issuance of Common Stock

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Simulations Plus Inc
Net Issuance of Common Stock Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Net Issuance of Common Stock CAGR 3Y CAGR 5Y CAGR 10Y
Simulations Plus Inc
NASDAQ:SLP
Net Issuance of Common Stock
$731k
CAGR 3-Years
-21%
CAGR 5-Years
-2%
CAGR 10-Years
22%
Veeva Systems Inc
NYSE:VEEV
Net Issuance of Common Stock
$75.6m
CAGR 3-Years
13%
CAGR 5-Years
39%
CAGR 10-Years
22%
Inspire Medical Systems Inc
NYSE:INSP
Net Issuance of Common Stock
$30.6m
CAGR 3-Years
26%
CAGR 5-Years
-16%
CAGR 10-Years
N/A
Doximity Inc
NYSE:DOCS
Net Issuance of Common Stock
-$264.4m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Omnicell Inc
NASDAQ:OMCL
Net Issuance of Common Stock
$13.4m
CAGR 3-Years
-44%
CAGR 5-Years
-35%
CAGR 10-Years
N/A
W
Waystar Holding Corp
NASDAQ:WAY
Net Issuance of Common Stock
-$263k
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Simulations Plus Inc
Glance View

Market Cap
568.2m USD
Industry
Health Care

Simulations Plus, Inc. provides modeling and simulation software and consulting services supporting drug discovery, development research and regulatory submissions. The company is headquartered in Lancaster, California and currently employs 135 full-time employees. The company provides prediction of properties of molecules utilizing artificial-intelligence- and machine-learning-based technology. The company also provides consulting services ranging from early drug discovery through preclinical and clinical trial development to regulatory submissions in support of product approval. The company offers 11 software products for pharmaceutical research and development, which includes GastroPlus, DDDPlus, MembranePlus, DILIsym, NAFLDsym, ADMET Predictor, MedChem Designer, MedChem Studio, PKPlus, KIWI and Monolix Suite of products through Lixoft. Its software and consulting services are provided to pharmaceutical, biotechnology, agrochemical, cosmetics, and food industry companies and to academic and regulatory agencies worldwide for use in the conduct of industry-based research. Cognigen Corporation, DILIsym Services, Inc. and Lixoft are its subsidiaries.

SLP Intrinsic Value
19.62 USD
Overvaluation 31%
Intrinsic Value
Price

See Also

What is Simulations Plus Inc's Net Issuance of Common Stock?
Net Issuance of Common Stock
731k USD

Based on the financial report for Aug 31, 2024, Simulations Plus Inc's Net Issuance of Common Stock amounts to 731k USD.

What is Simulations Plus Inc's Net Issuance of Common Stock growth rate?
Net Issuance of Common Stock CAGR 10Y
22%

The average annual Net Issuance of Common Stock growth rates for Simulations Plus Inc have been -21% over the past three years , -2% over the past five years , and 22% over the past ten years .

Back to Top